Eicosanoid synthesis pathway enzymes

The eicosanoid synthesis pathway enzymes are a collective group of enzymes that catalyze the conversion of polyunsaturated fatty acids, primarily arachidonic acid, into potent lipid signaling molecules known as eicosanoids (Source: NIH, 2024). This complex enzymatic network includes phospholipase A2 (PLA2), which initiates the pathway by releasing arachidonic acid from cell membranes, and three major downstream branches: the cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) pathways (Source: StatPearls, 2023). These enzymes produce a variety of mediators, such as prostaglandins, thromboxanes, and leukotrienes, which regulate critical physiological processes including inflammation, fever, pain perception, and vascular homeostasis (Source: Wikipedia, 2024). Dysregulation of these enzymes is a hallmark of numerous pathological conditions, particularly chronic inflammatory diseases, asthma, and certain cancers (Source: PubMed, 2022). Pharmacological modulation of these enzymes is a cornerstone of modern medicine; for example, non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen target COX enzymes to reduce pain and inflammation, while 5-LOX inhibitors like zileuton are used to treat asthma (Source: NIH, 2024). However, targeting these pathways requires careful management due to potential side effects such as gastrointestinal bleeding and cardiovascular risks (Source: StatPearls, 2023).

Other names

Arachidonic acid metabolism enzymesArachidonic acid cascade enzymesProstanoid and leukotriene synthesis enzymesOxylipin biosynthetic enzymes

Inhibition of specific enzymes within the pathway, such as cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), or 5-lipoxygenase (5-LOX), to prevent the synthesis of pro-inflammatory and pro-thrombotic lipid mediators from arachidonic acid.